Instituto de Investigación e Innovación en Ciencias Biomédicas (INiBICA)

2024

1. Actividad Física, Ejercicio y Salud: Retos Actuales y Desafíos Futuros

   Revista Andaluza de Medicina del Deporte

2. Assessing the value of moderate-to-severe atopic dermatitis treatment using multi-criteria decision analysis (MCDA)

   Journal of the European Academy of Dermatology and Venereology

3. Bilateral primary motor area intermittent theta-burst stimulation may alleviate gait and postural disturbances in Parkinson's disease patients by astrocytic modulation, caudate volume changes, and increased functional neuroplasticity

   Parkinsonism and Related Disorders

4. Correction to: Association between co-sleeping in the first year of life and preschoolers´ sleep patterns(European Journal of Pediatrics, 10.1007/s00431-024-05429-2)

   European Journal of Pediatrics

5. Correction to: Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab versus Dupilumab in Moderate-to-Severe Atopic Dermatitis (Dermatology and Therapy, (2024), 14, 1, (169-182), 10.1007/s13555-023-01058-z)

   Dermatology and Therapy

6. Editorial: Editors showcase 2023: insights in stem cell research

   Frontiers in Cell and Developmental Biology

7. In vitro susceptibility to delafloxacin of Pseudomonas aeruginosa with resistance to other quinolones (ciprofloxacin and levofloxacin)

   Clinical Microbiology and Infection

8. Optimal timing of antibiotic administration in septic patients: The need to reformulate this question

   European Journal of Internal Medicine

9. Rate of recurrence after discontinuing anticoagulation in patients with venous thromboembolism within 30 days after COVID-19 vaccine

   European Journal of Clinical Investigation

10. Response to “Letter to the Editor Regarding ‘Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis’”

    Dermatology and Therapy